Pharma Mar (PHM.MC)

Executive Summary

Pharma Mar is a Spanish biopharmaceutical company specializing in marine-derived oncology therapies, with its approved drug Yondelis® (trabectedin) for soft tissue sarcoma and ovarian cancer. The company leverages a proprietary platform to discover novel compounds from ocean organisms, aiming to address high unmet needs in oncology. Despite a broad pipeline, recent focus has been on lurbinectedin for small cell lung cancer and other solid tumors, with potential label expansions and combination therapies. The company's financial health is supported by Yondelis sales and collaborations, but competition and regulatory hurdles remain challenges. With a market cap of ~€1.7B, Pharma Mar is positioned for growth if pipeline milestones are met, though near-term catalysts are critical for valuation.

Upcoming Catalysts (preview)

• Q3 2026Lurbinectedin Phase 3 data in SCLC70% success
• Q4 2026Yondelis label expansion for ovarian cancer maintenance50% success
• TBDPartnership or licensing deal for early-stage pipeline40% success